Patents by Inventor John A. Tine

John A. Tine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof
    Publication number: 20130216563
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 22, 2013
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
    Patent number: 8257717
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: September 4, 2012
    Assignees: Sanofi Pasteur Limited, Ludwig Institute for Cancer Research
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof
    Publication number: 20110250234
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Application
    Filed: October 27, 2010
    Publication date: October 13, 2011
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
    Patent number: 7851212
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: December 14, 2010
    Assignees: Sanofi Pasteur Limited, Ludwig Institute for Cancer Research
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Immunogenic polypetides encoded by mage minigenes and uses thereof
    Publication number: 20040033234
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Application
    Filed: July 8, 2003
    Publication date: February 19, 2004
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Malaria recombinant poxviruses
    Patent number: 5766597
    Abstract: What is described is a recombinant poxvirus, such as vaccinia or canarypox virus, containing foreign DNA from Plasmodium such as coding for at least one of CSP, PfSSP2, LSA-1, LSA-1-repeatless, MSA-1, SERA, AMA-1, Pfs25, MSA-1 N-terminal p83 and MSA-1 C-terminal gp42. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. Preferred recombinants have attenuated virulence. In certain embodiments the vaccinia has deleted or disrupted the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the host range gene region and, the large subunit, ribonucleotide reductase; and, contains coding sequences for CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. That embodiment is termed NYVAC-Pf7 and is a multicomponent, multistage vaccine since it codes for and expresses sporozoite proteins, liver stage proteins, blood stage proteins and, sexual stage proteins.
    Type: Grant
    Filed: June 9, 1994
    Date of Patent: June 16, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Charles de Taisne, John A. Tine